Skip to Main

Oppenheimer Acted as Lead Manager for Milestone Pharmaceuticals Inc.

  • Oppenheimer & Co. Inc.
  • July 18, 2019

Milestone, headquartered in Montreal, Canada with a U.S. subsidiary in Charlotte, N.C., is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT) as they occur.

For more information please contact:

Healthcare Investment Banking                                                     Equity Capital Markets
Michael A. Margolis, R.Ph.                                                             Peter Bennett
Co-Head of Healthcare Investment Banking                                   Head of Equity Capital Markets
212-667-7622                                                                                212-667-6285                                              

Stefan Loren, Ph.D.
Managing Director


This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

Oppenheimer and Oppenheimer Asset Management Inc (OAM) are principle subsidiaries of Oppenheimer Holdings Inc., and provide a full range of wealth management, securities brokerage, capital markets, and investment banking services to high-net worth individuals, families, corporate executives, businesses and institutions. The Firm creates integrated financial strategies tailored to each client’s goals. For over 130 years of operation, Oppenheimer has emphasized customer service, integrity and intellectual objectivity.

2019 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 2550967.1